Zepbound coupon: where to get it
Reviewed by Felix Gussone, MD, Ro,
Written by Yael Cooperman, MD, Ro
LAST UPDATED: Nov 09, 2023
1 MIN READ
HERE'S WHAT WE'LL COVER
Zepbound, a medication approved by the FDA for weight loss, is expected to be available soon but the price may be prohibitive for some. That’s why the manufacturer has made a coupon that may offer significant savings on the drug. We spoke with Dr. Yael Cooperman, M.D. about where to get a coupon for Zepbound and when the drug might be available.
body program
Fad diets stop here
If appropriate, get effective weight loss treatment prescribed for your body.
Zepbound coupons
Zepbound (tirzepatide) will soon be available for the treatment of overweight and obesity, according to manufacturer Eli Lilly. Since it is expected to cost around $1,023 per month for the once-weekly shots, Eli Lilly will offer a manufacturer’s coupon for the drug that may help patients save significantly and spend as little as $25 for a one- or three-month supply of the medication.
To qualify for these savings, you must have private insurance coverage that includes treatment with weight loss medications. People with government insurance coverage (such as Medicare and Medicaid) do not qualify for these medications. If you have private insurance coverage but your insurance does not cover weight loss medications, you still may qualify for savings of up to $563 a month, which is about 50% off the list price.
How to get Zepbound for weight loss
To get Zepbound for weight loss, you will need a prescription from a licensed healthcare provider. They will review your medical history to see if you are a good candidate for treatment with Zepbound or another medication. If they decide that Zepbound is the right treatment for you, the medication is expected to be available after Thanksgiving 2023, according to CEO of the drug’s manufacturer Eli Lilly, David Ricks.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Chen, E. & Garde, D. (2023). Eli Lilly Gets FDA Approval to Sell Mounjaro as Obesity Drug Called Zepbound. STAT. Retrieved Nov. 9, 2023 from https://www.statnews.com/2023/11/08/obesity-eli-lilly-mounjaro-zepbound-fda/
U.S. Food and Drug Administration (FDA). FDA Approves New Medication for Chronic Weight Management. Office of the Commissioner. Retrieved Nov. 8, 2023 from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
How we reviewed this article
Every article on Health Guide goes through rigorous fact-checking by our team of medical reviewers. Our reviewers are trained medical professionals who ensure each article contains the most up-to-date information, and that medical details have been correctly interpreted by the writer.
Current version
November 09, 2023
Written by
Yael Cooperman, MD
Fact checked by
Felix Gussone, MD
About the medical reviewer
Felix Gussone is a physician, health journalist and a Manager, Medical Content & Education at Ro.
